The following are some of the healthcare sector stocks that moved up in after-hours trading on Monday.
FibroGen Inc. (FGEN) has reported financial results for the first quarter of 2024 and provided an update on the upcoming anticipated milestones. The company markets Roxadustat in China, Europe, Japan, and numerous other countries for the treatment of anemia of CKD in adult patients on dialysis (DD) and not on dialysis (NDD). The total revenue for the first quarter of 2024 was $55.9 million, compared to $36.2 million for the first quarter of 2023, driven by net product revenue in China and one-time drug product revenue of $25.7 million recognized due to the termination of US/RoW AstraZeneca agreement. Net loss for the first quarter of 2024 narrowed to $32.9 million, or $0.33 per share from $76.7 million, or $0.81 pern share in the year-ago quarter.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.